Entering text into the input field will update the search result below

IMF March Buys: The 12 Stocks Added To My Fund

Apr. 04, 2021 8:17 PM ETAI, BF.A, BF.B, CELL, ED, FAF, FLIC, JNJ, NAPA, OMAB, RBLX, REYN, U29 Comments


  • 11 buys and 1 dividend reinvestment for March.
  • Thanks to a major market rotation, tech stocks are finally worth buying again.
  • To that end, we have three new tech picks this month, along with a new position in a winery IPO.
  • Looking for a helping hand in the market? Members of Ian's Insider Corner get exclusive ideas and guidance to navigate any climate. Learn More »

Ian's Million Fund, "IMF," is a real-money portfolio that I've written about monthly since January 2016 here at Seeking Alpha. The portfolio is a largely buy-and-hold group of ~130 stocks. Each month, I buy 10-20 of the most compelling stocks available at then-current prices, deploying $1,000 of my capital plus accumulated dividends. If things go according to plan, this portfolio, which began when I was 27, will hit one million dollars in equity in 2041 at age 52. I intend it to serve as a model for other younger investors.

I made this month's purchases on March 25. There was a lot of volatility this past month, but the market overall never corrected. As such, there wasn't any particularly compelling moment to go on a shopping spree, however I did take advantage of the drop in tech stocks. Here's what I bought in March:

For the dividend reinvestment this month, that all went into Reynolds (REYN). I'd been splitting it between Reynolds and Hormel (HRL) recently, but Hormel has bounced off its lows, so Reynolds gets the nod thanks to relative valuation. While the market is sleeping on the name, I reiterate my call for REYN stock to hit $40 this year.

Old Favorites Make A Return

We have additions this month to a few "classic" IMF stocks that had been off the buy-list for a while.

For one, I added shares of Centro Norte Airports (OMAB) for the first time since the height of the pandemic last summer. OMAB stock has fallen back from $61 (where it had recovered all its Covid-19 losses) to $50 in recent days with the slowdown in European vaccinations.

Does that matter to the bull case for OMAB stock? No, not really. But when the stock had doubled in a matter of months, any sort of excuse could

Data by YCharts

Data by YCharts

Data by YCharts

The three pure growth stocks I started buying this month have all suffered dramatic pullbacks over the past quarter.

This is an Ian's Insider Corner report published March 25th for our service's subscribers. If you enjoyed this, consider our service to enjoy access to similar initiation reports for all the new stocks that we buy. Membership also includes an active chat room, weekly updates, and my responses to your questions.

This article was written by

Ian Bezek profile picture
Research and trade alerts from a hedge fund pro with a global outlook.

Ian worked for Kerrisdale, a New York activist hedge fund, for three years, before moving to Latin America to pursue entrepreneurial opportunities there. His Ian's Insider Corner service provides live chat, model portfolios, full access and updates to his "IMF" portfolio, along with a weekly newsletter which expands on these topics.

Analyst’s Disclosure: I am/we are long ALL THE STOCKS IN THE TABLE. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.